Published Date: 20-Jan-2023
Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
According to a new report, published by KBV research, The Global Healthcare Bioconvergence Market size is expected to reach $169.9 billion by 2028, rising at a market growth of 7.0% CAGR during the forecast period.
The Drug Discovery segment acquired maximum revenue share in the Global Healthcare Bioconvergence Market by Application in 2021 thereby, achieving a market value of $40 billion by 2028. Due to rising healthcare expenditures, an increase in the prevalence of a wide range of ailments (including cardiovascular and CNS-related disorders), and the upcoming patent expirations of well-known drugs. The increasing effects of a wide variety of illnesses across all age groups globally drove the demand for drug research. The regenerative medicine segment is growing at a fast rate.
The Europe market dominated the Global Healthcare Bioconvergence Market by Region in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $56.30 billion by 2028. The North America market is exhibiting a CAGR of 6.7% during (2022 - 2028). Additionally, The Asia Pacific market would showcase a CAGR of 7.4% during (2022 - 2028).
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of BiomX, Inc., Singota Solutions, Anima Biotech Inc., Ginkgo Bioworks Holdings, Inc., SetPoint Medical Corporation, Galvani Bioelectronics, Ltd. (GlaxoSmithKline plc and Verily Life Sciences), and BICO Group AB (publ)
Unique Offerings from KBV Research